

Diabetes: A Disease of Epidemic Proportions²

The world is battling diabetes. AstraZeneca's ambition is to be a leader in that fight.


What Is Diabetes?



Occurs when the body has insufficient insulin production or is unable to respond to its effects¹



This can lead to a build-up of glucose in the blood [hyperglycaemia]¹



Type 2 diabetes is the most commonly diagnosed form of diabetes²



People with type-2 diabetes can remain undiagnosed for many years, unaware of the long-term damage being caused²



Significant unmet needs exist as many patients remain uncontrolled on their current treatment regimen³



If untreated, diabetes can lead to serious complications & early death²

The Global Diabetes Burden


Incidence of type 2 diabetes is increasing across the globe²

425 million

people, or 8.8% of adults 20-79 years worldwide are estimated to have diabetes

79%

of people with diabetes live in low and middle income countries²



Type 2 diabetes accounts for around **90%** of all diagnosed cases of diabetes²

Diabetes is projected to affect up to

629 million people by 2045²



Demand is rising for treatments that meet individual patient needs²

30-80% of people with diabetes remain undiagnosed²

AstraZeneca & Diabetes



Seeking to positively impact the lives of patients to help reduce the disease burden and its complications



First company to offer products in all three of the newest, fastest-growing classes of type 2 diabetes treatments:

- SGLT2 inhibitors
- GLP-1 receptor agonists
- DPP-4 inhibitors



Focused on advancing the treatment paradigm to use combination therapies to help more patients achieve their treatment goals⁴

Committed to:



Ushering in a new era of innovative diabetes care



Pursuing scientific excellence to address patients' unmet needs



Investing in R&D that may help discover novel treatment pathways



Offering individualised approaches to care

1. American Diabetes Association (ADA). Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2009;32(1):62-67

2. International Diabetes Federation. IDF Diabetes Atlas, 8th ed. Brussels, Belgium: International Diabetes Federation, 2017.

3. Cheung B, Lond, Edin et al. Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999-2006. American Journal of Medicine 2009;122:443-453.

4. DeFronzo RA. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes. 2009;58(774).

For media use - please obtain local nominated signatory approval before use